Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The WEST Study
NCT00121446Phase 3Completed
- Sponsor
- University of Alberta
- Start
- Jul 2003
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in ST elevation myocardial infarction (STEMI) (3 arms), sponsored by University of Alberta. Primary endpoint: Composite of death, recurrent myocardial infarction, heart failure, cardiogenic shock, refractory ischemia, major ventricular arrhythmia at 30 days. Started Jul 2003; status: completed.
02
Drugs
tenecteplase
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT00121446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121446.